Physician profile
Arun Padala
NPI 1982803458
$5,416.96
in general payments reported to CMS, 2019-2025
27 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $434 · 2021: $815 · 2022: $449 · 2023: $772 · 2024: $670 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,222.01 | 2019-2020 | |
| Abbott Laboratories | $684.25 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Abiomed | $583.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $412.53 | 2021-2025 | |
| Pfizer INC. | $264.91 | 2019-2025 | |
| Boston Scientific Corporation | $259.61 | 2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $253.61 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $252.08 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $214.90 | 2023-2025 | Verquvo |
| Biotronik INC. | $127.61 | 2022 | |
| Heartflow, INC. | $126.33 | 2022 | |
| Amgen INC. | $123.84 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $119.32 | 2025 | Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.04 | 2020-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $107.11 | 2019-2024 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $106.66 | 2023 | Micra |
| Lexicon Pharmaceuticals, INC. | $88.21 | 2024 | |
| Inspire Medical Systems, INC. | $79.42 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $58.15 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.20 | 2024-2025 | Jardiance |
| Cardiovascular Systems INC. | $39.94 | 2019 | |
| Irhythm Technologies, INC. | $29.18 | 2023 | Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $26.40 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $23.14 | 2021 | |
| Amarin Pharma, INC. | $17.48 | 2022 | |
| Angiodynamics, INC. | $16.74 | 2022 | |
| Avinger INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Padala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.